AzurRx BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZRX research report →
Price Chart
About the company
AzurRx BioPharma, Inc. , a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101.
- CEO
- James Sapirstein
- IPO
- 2016
- Employees
- 12
- HQ
- Brooklyn, NY, US
Get TickerSpark's AI analysis on AZRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.43M
- P/E
- -0.83
- PEG
- 0.01
- P/S
- 165.01
- P/B
- 2.48
- EV/EBITDA
- -2.68
- Div Yield
- 0.00%
- Gross Margin
- -1234.52%
- Op Margin
- -7544.25%
- Net Margin
- -11284.14%
- ROE
- -112.82%
- ROIC
- -57.23%
Latest fiscal year · YoY change
- Revenue
- $36.25K+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,083,438
- Net Income
- $-6,553,578+63.7%
- EPS
- $-4.16+22.0%
- OCF Growth
- +38.1%
- FCF Growth
- +38.1%
- 52W High
- $26.30
- 52W Low
- $2.68
- 50D MA
- $4.94
- 200D MA
- $7.50
- Beta
- 1.51
- RSI (14)
- 28
- Avg Volume
- 713.03K
No earnings-call transcripts are available for AZRX yet.
- Free Float
- 78.9%
- Shares Outstanding
- 995.00K
- Float Shares
- 784.80K
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Commonwealth Equity Services, Inc | 14.25K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 21 | Coelho Mary Theresa | other | 10,310 |
| Aug 11, 21 | Coelho Mary Theresa | other | 0 |
| Jul 9, 21 | Pennington James | other | 100,000 |
| Jun 30, 21 | Schneiderman Daniel H | other | 250,000 |
| Jun 30, 21 | Schneiderman Daniel H | other | 35,006 |
| Jun 30, 21 | Schneiderman Daniel H | other | 250,000 |
| Jun 30, 21 | SAPIRSTEIN JAMES | other | 900,000 |
| Jun 30, 21 | SAPIRSTEIN JAMES | other | 900,000 |
| Jan 4, 21 | Oakes Gregory | other | 41,237 |
| Jan 4, 21 | BORKOWSKI EDWARD | other | 41,237 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AZRX coverage
Recent articles, reports, and earnings notes.
No research on AZRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZRX report →AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
globenewswire.com · Sep 21
3 Penny Stocks That Top Investors Buying Right Now
pennystocks.com · Sep 15
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
zacks.com · Sep 14
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
globenewswire.com · Sep 14
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
seekingalpha.com · Sep 13
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
benzinga.com · Sep 13
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
globenewswire.com · Sep 13
AzurRx BioPharma Announces Reverse Stock Split
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.